Literature DB >> 26696260

Acceptability and Preferences for Hypothetical Rectal Microbicides among a Community Sample of Young Men Who Have Sex with Men and Transgender Women in Thailand: A Discrete Choice Experiment.

Peter A Newman1, Michael P Cameron2, Surachet Roungprakhon3, Suchon Tepjan4, Riccardo Scarpa2.   

Abstract

Rectal microbicides (RMs) may offer substantial benefits in expanding HIV prevention options for key populations. From April to August 2013, we conducted Tablet-Assisted Survey Interviewing, including a discrete choice experiment, with participants recruited from gay entertainment venues and community-based organizations in Chiang Mai and Pattaya, Thailand. Among 408 participants, 74.5 % were young men who have sex with men, 25.5 % transgender women, with mean age = 24.3 years. One-third (35.5 %) had ≤9th grade education; 63.4 % engaged in sex work. Overall, 83.4 % reported they would definitely use a RM, with more than 2-fold higher odds of choice of a RM with 99 versus 50 % efficacy, and significantly higher odds of choosing gel versus suppository, intermittent versus daily dosing, and prescription versus over-the-counter. Sex workers were significantly more likely to use a RM immediately upon availability, with greater tolerance for moderate efficacy and daily dosing. Engaging key populations in assessing RM preferences may support biomedical research and evidence-informed interventions to optimize the effectiveness of RMs in HIV prevention.

Entities:  

Keywords:  Discrete choice experiment; HIV; Male sex workers; Rectal microbicides; Thailand; Transgender women; Young men who have sex with men (YMSM)

Mesh:

Substances:

Year:  2016        PMID: 26696260     DOI: 10.1007/s10461-015-1258-9

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  20 in total

1.  MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.

Authors:  Ross D Cranston; Javier R Lama; Barbra A Richardson; Alex Carballo-Diéguez; Ratiya Pamela Kunjara Na Ayudhya; Karen Liu; Karen B Patterson; Cheng-Shiun Leu; Beth Galaska; Cindy E Jacobson; Urvi M Parikh; Mark A Marzinke; Craig W Hendrix; Sherri Johnson; Jeanna M Piper; Cynthia Grossman; Ken S Ho; Jonathan Lucas; Jim Pickett; Linda-Gail Bekker; Suwat Chariyalertsak; Anupong Chitwarakorn; Pedro Gonzales; Timothy H Holtz; Albert Y Liu; Kenneth H Mayer; Carmen Zorrilla; Jill L Schwartz; James Rooney; Ian McGowan
Journal:  Clin Infect Dis       Date:  2017-03-01       Impact factor: 9.079

Review 2.  Designing and developing suppository formulations for anti-HIV drug delivery.

Authors:  Anthony S Ham; Robert W Buckheit
Journal:  Ther Deliv       Date:  2017-08

3.  The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis.

Authors:  Hae-Young Kim; Colleen F Hanrahan; David W Dowdy; Neil Martinson; Jonathan Golub; John F P Bridges
Journal:  AIDS Care       Date:  2018-03-29

4.  Maternal Motivation to Take Preventive Therapy in Antepartum and Postpartum Among HIV-Positive Pregnant Women in South Africa: A Choice Experiment.

Authors:  Hae-Young Kim; David W Dowdy; Neil A Martinson; Deanna Kerrigan; Carrie Tudor; Jonathan Golub; John F P Bridges; Colleen F Hanrahan
Journal:  AIDS Behav       Date:  2019-07

5.  Willingness to Use Pre-exposure Prophylaxis (PrEP) and Preferences Among Men Who have Sex with Men in Mumbai and Chennai, India: A Discrete Choice Experiment.

Authors:  Venkatesan Chakrapani; Peter A Newman; Michael Cameron; Murali Shunmugam; Surachet Roungprakhon; Shruta Rawat; Dicky Baruah; Ruban Nelson; Suchon Tepjan; Riccardo Scarpa
Journal:  AIDS Behav       Date:  2021-04-05

Review 6.  PrEP Product Acceptability and Dual Process Decision-Making Among Men Who Have Sex with Men.

Authors:  José A Bauermeister; Julie S Downs; Douglas S Krakower
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

7.  Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey.

Authors:  Catherine E Oldenburg; Bao Le; Hoang Thi Huyen; Dinh Duc Thien; Nguyen Hoang Quan; Katie B Biello; Amy Nunn; Philip A Chan; Kenneth H Mayer; Matthew J Mimiaga; Donn Colby
Journal:  Sex Health       Date:  2016-07-22       Impact factor: 2.706

8.  Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.

Authors:  Alex Carballo-Diéguez; Rebecca Giguere; Curtis Dolezal; Cheng-Shiun Leu; Iván C Balán; William Brown; Christine Rael; Barbra A Richardson; Jeanna M Piper; Linda-Gail Bekker; Suwat Chariyalertsak; Anupong Chitwarakorn; Pedro Gonzales; Timothy H Holtz; Albert Liu; Kenneth H Mayer; Carmen D Zorrilla; Javier R Lama; Ian McGowan; Ross D Cranston
Journal:  AIDS Behav       Date:  2017-12

9.  A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S.

Authors:  Jane M Simoni; Kenneth Tapia; Sung-Jae Lee; Susan M Graham; Kristin Beima-Sofie; Zahra H Mohamed; Joan Christodoulou; Rodney Ho; Ann C Collier
Journal:  AIDS Behav       Date:  2020-04

10.  Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.

Authors:  Ian McGowan; Ross D Cranston; Kenneth H Mayer; Irma Febo; Kathryn Duffill; Aaron Siegel; Jarret C Engstrom; Alexyi Nikiforov; Seo-Young Park; Rhonda M Brand; Cindy Jacobson; Rebecca Giguere; Curtis Dolezal; Timothy Frasca; Cheng-Shiun Leu; Jill L Schwartz; Alex Carballo-Diéguez
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.